MR Imaging for Assessment of Breast Cancer Response to Neoadjuvant Chemotherapy

Magnetic Resonance Imaging Clinics of North America

Volumn 14, Issue 3, 2006, Pages 383-389

  Hylton, Nola ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN;

ADJUVANT CHEMOTHERAPY; BREAST CANCER; CANCER EPIDEMIOLOGY; CANCER INHIBITION; CANCER STAGING; CLINICAL EXAMINATION; CONTRAST ENHANCEMENT; DIAGNOSTIC ACCURACY; DISEASE CLASSIFICATION; ECHOGRAPHY; HISTOPATHOLOGY; HUMAN; MAMMOGRAPHY; MASTECTOMY; MINIMAL RESIDUAL DISEASE; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PARTIAL MASTECTOMY; REVIEW; SENSITIVITY ANALYSIS;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; CONTRAST MEDIA; FEMALE; HUMANS; MAGNETIC RESONANCE IMAGING; NEOADJUVANT THERAPY; NEOPLASM, RESIDUAL; RANDOMIZED CONTROLLED TRIALS;

EID: 33846009438     PISSN: 10649689     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mric.2006.09.001     Document Type: Review

References (38)

1. Fisher B., Bryant J., Wolmark N., et al. Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J Clin Oncol 16 (1998) 2672-2685
2. Wolmark N., Wang J., Mamounas E., et al. Preoperative chemotherapy in patients with operable breast cancer: nine-year results from National Surgical Adjuvant Breast and Bowel Project B-18. J Natl Cancer Inst Monogr (2001) 96-102
3. Makris A., Powles T.J., Ashley S.E., et al. A reduction in the requirements for mastectomy in a randomized trial of neoadjuvant chemoendocrine therapy in primary breast cancer. Ann Oncol 9 (1998) 1179-1184
4. Mauriac L., MacGrogan G., Avril A., et al. Neoadjuvant chemotherapy for operable breast carcinoma larger than 3 cm: a unicentre randomized trial with a 124-month median follow-up. Institut Bergonie Bordeaux Groupe Sein (IBBGS). Ann Oncol 10 (1999) 47-52
5. Broet P., Scholl S.M., de la Rochefordiere A., et al. Short and long-term effects on survival in breast cancer patients treated by primary chemotherapy: an updated analysis of a randomized trial. Breast Cancer Res Treat 58 (1999) 151-156
6. Mumtaz H., Hall-Craggs M.A., Davidson T., et al. Staging of symptomatic primary breast cancer with MR imaging. AJR Am J Roentgenol 169 (1997) 417-424
7. Van Goethem M., Schelfout K., Dijckmans L., et al. MR mammography in the pre-operative staging of breast cancer in patients with dense breast tissue: comparison with mammography and ultrasound. Eur Radiol 14 (2004) 809-816
8. Esserman L., Hylton N., Yassa L., et al. Utility of magnetic resonance imaging in the management of breast cancer: evidence for improved preoperative staging. J Clin Oncol 17 (1999) 110-119
9. Kramer S., Schulz-Wendtland R., Hagedorn K., et al. Magnetic resonance imaging and its role in the diagnosis of multicentric breast cancer. Anticancer Res 18 (1998) 2163-2164
10. Boetes C., Mus R.D., Holland R., et al. Breast tumors: comparative accuracy of MR imaging relative to mammography and US for demonstrating extent. Radiology 197 (1995) 743-747
11. Davis P.L., Staiger M.J., Harris K.B., et al. Breast cancer measurements with magnetic resonance imaging, ultrasonography, and mammography. Breast Cancer Res Treat 37 (1996) 1-9
12. Drew P.J., Kerin M.J., Mahapatra T., et al. Evaluation of response to neoadjuvant chemoradiotherapy for locally advanced breast cancer with dynamic contrast-enhanced MRI of the breast. Eur J Surg Oncol 27 (2001) 617-620
13. Partridge S.C., Gibbs J.E., Lu Y., et al. Accuracy of MR imaging for revealing residual breast cancer in patients who have undergone neoadjuvant chemotherapy. AJR Am J Roentgenol 179 (2002) 1193-1199
14. Londero V., Bazzocchi M., Del Frate C., et al. Locally advanced breast cancer: comparison of mammography, sonography and MR imaging in evaluation of residual disease in women receiving neoadjuvant chemotherapy. Eur Radiol 14 (2004) 1371-1379
15. Yeh E., Slanetz P., Kopans D.B., et al. Prospective comparison of mammography, sonography, and MRI in patients undergoing neoadjuvant chemotherapy for palpable breast cancer. AJR Am J Roentgenol 184 (2005) 868-877
16. Montemurro F., Martincich L., De Rosa G., et al. Dynamic contrast-enhanced MRI and sonography in patients receiving primary chemotherapy for breast cancer. Eur Radiol 15 (2005) 1224-1233
17. Akazawa K., Tamaki Y., Taguchi T., et al. Preoperative evaluation of residual tumor extent by three-dimensional magnetic resonance imaging in breast cancer patients treated with neoadjuvant chemotherapy. Breast J 12 (2006) 130-137
18. Schott A.F., Roubidoux M.A., Helvie M.A., et al. Clinical and radiologic assessments to predict breast cancer pathologic complete response to neoadjuvant chemotherapy. Breast Cancer Res Treat 92 (2005) 231-238
19. Abraham D.C., Jones R.C., Jones S.E., et al. Evaluation of neoadjuvant chemotherapeutic response of locally advanced breast cancer by magnetic resonance imaging. Cancer 78 (1996) 91-100
20. Balu-Maestro C., Chapellier C., Bleuse A., et al. Imaging in evaluation of response to neoadjuvant breast cancer treatment benefits of MRI. Breast Cancer Res Treat 72 (2002) 145-152
21. Weatherall P.T., Evans G.F., Metzger G.J., et al. MRI vs. histologic measurement of breast cancer following chemotherapy: comparison with x-ray mammography and palpation. J Magn Reson Imaging 13 (2001) 868-875
22. Kwong M.S., Chung G.G., Horvath L.J., et al. Postchemotherapy MRI overestimates residual disease compared with histopathology in responders to neoadjuvant therapy for locally advanced breast cancer. Cancer J 12 (2006) 212-221
23. Rieber A., Brambs H.J., Gabelmann A., et al. Breast MRI for monitoring response of primary breast cancer to neo-adjuvant chemotherapy. Eur Radiol 12 (2002) 1711-1719
24. Wasser K., Sinn H.P., Fink C., et al. Accuracy of tumor size measurement in breast cancer using MRI is influenced by histological regression induced by neoadjuvant chemotherapy. Eur Radiol 13 (2003) 1213-1223
25. Denis F., Desbiez-Bourcier A.V., Chapiron C., et al. Contrast enhanced magnetic resonance imaging underestimates residual disease following neoadjuvant docetaxel based chemotherapy for breast cancer. Eur J Surg Oncol 30 (2004) 1069-1076
26. Warren R.M., Bobrow L.G., Earl H.M., et al. Can breast MRI help in the management of women with breast cancer treated by neoadjuvant chemotherapy?. Br J Cancer 90 (2004) 1349-1360
27. Rosen E.L., Blackwell K.L., Baker J.A., et al. Accuracy of MRI in the detection of residual breast cancer after neoadjuvant chemotherapy. AJR Am J Roentgenol 181 (2003) 1275-1282
28. Therasse P., Arbuck S.G., Eisenhauer E.A., et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92 (2000) 205-216
29. Martincich L., Montemurro F., De Rosa G., et al. Monitoring response to primary chemotherapy in breast cancer using dynamic contrast-enhanced magnetic resonance imaging. Breast Cancer Res Treat 83 (2004) 67-76
30. Pickles M.D., Lowry M., Manton D.J., et al. Role of dynamic contrast enhanced MRI in monitoring early response of locally advanced breast cancer to neoadjuvant chemotherapy. Breast Cancer Res Treat 91 (2005) 1-10
31. Padhani A.R., Hayes C., Assersohn L., et al. Prediction of clinicopathologic response of breast cancer to primary chemotherapy at contrast-enhanced MR imaging: initial clinical results. Radiology 239 (2006) 361-374
32. Cheung Y.C., Chen S.C., Su M.Y., et al. Monitoring the size and response of locally advanced breast cancers to neoadjuvant chemotherapy (weekly paclitaxel and epirubicin) with serial enhanced MRI. Breast Cancer Res Treat 78 (2003) 51-58
33. Manton D.J., Chaturvedi A., Hubbard A., et al. Neoadjuvant chemotherapy in breast cancer: early response prediction with quantitative MR imaging and spectroscopy. Br J Cancer 94 (2006) 427-435
34. Wasser K., Klein S.K., Fink C., et al. Evaluation of neoadjuvant chemotherapeutic response of breast cancer using dynamic MRI with high temporal resolution. Eur Radiol 13 (2003) 80-87
35. Murata Y., Ogawa Y., Yoshida S., et al. Utility of initial MRI for predicting extent of residual disease after neoadjuvant chemotherapy: analysis of 70 breast cancer patients. Oncol Rep 12 (2004) 1257-1262
36. Esserman L., Kaplan E., Partridge S., et al. MRI phenotype is associated with response to doxorubicin and cyclophosphamide neoadjuvant chemotherapy in stage III breast cancer. Ann Surg Oncol 8 (2001) 549-559
37. Martincich L., Montemurro F., Cirillo S., et al. Role of magnetic resonance imaging in the prediction of tumor response in patients with locally advanced breast cancer receiving neoadjuvant chemo-therapy. Radiol Med (Torino) 106 (2003) 51-58
38. Partridge S.C., Gibbs J.E., Lu Y., et al. MRI measurements of breast tumor volume predict response to neoadjuvant chemotherapy and recurrence-free survival. AJR Am J Roentgenol 184 (2005) 1774-1781